NIBSC - Reagents

Enter a search term

Home Page > Spotlight > Influenza Resource Centre > Reagents

Reagents

Full Reagent Update

Current availability from NIBSC of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2013/2014 northern hemisphere and the 2013 southern hemisphere season. (See below for pricing information)

Update 41, 06 May 2013

Northern Hemisphere 2013/2014¹

Candidate influenza vaccine viruses	NIBSC code
H1N1
A/California/7/2009 wild type virus	12/174
NYMC X-179A reassortant derived from A/California/7/2009	11/112
NYMC X-181 reassortant derived from A/California/7/2009	11/128
NIBRG-121xp reassortant derived from A/California/7/2009	09/268
NIBRG-122 reassortant derived from A/England/195/2009 (A/California/7/2009 – like)	09/130
NIB-74xp reassortant derived from A/Christchurch/16/2010 (A/California/7/2009 – like)	11/186
H3N2
A/Texas/50/2012 wild type virus	12/298
NYMC X-223A reassortant derived from A/Texas/50/2012	12/286
NYMC X-223 reassortant derived from A/Texas/50/2012	12/292
B (Yamagata lineage)
B/Massachusetts/2/2012 wild type virus	12/288
NYMC BX-51B reassortant derived from B/Massachusetts/2/2012	12/296
NYMC BX-51C reassortant derived from B/Massachusetts/2/2012	12/294
B (Victoria lineage)
B/Brisbane/60/2008	12/200
B/Brisbane/33/2008	08/280
NYMC BX-31 reassortant derived from B/Brisbane/60/2008	10/276
NYMC BX-35 reassortant derived from B/Brisbane/60/2008	09/318

Reagents for influenza vaccine standardisation	NIBSC code
H1N1
A/California/7/2009 (NYMC X-179A) egg derived antigen	N/A
A/California/7/2009 (NYMC X-179A) cell derived antigen	09/174
A/California/7/2009 (NIBRG-121xp) egg derived antigen	09/196
A/California/7/2009 (NYMC X-181)	12/168
A/Christchurch/16/2010 (NIB-74)	10/258
A/Brisbane/10/2010 cell derived antigen	11/134
A/California/7/2009 antiserum	12/108
H3N2
A/Texas/50/2012 (NYMC-X223) egg derived antigen	13/112
A/Texas/50/2012 (NYMC-X223A) egg derived antigen	tbc
A/Texas/50/2012-Like antiserum	13/110
B (Yamagata lineage)
B/Massachusetts/02/2012 egg derived antigen	tbc
B/Massachusetts/02/2012 cell derived antigen	tbc
B/Massachusetts/02/2012 (NYMCBX-51B) egg derived antigen	13/106
B/Massachusetts/02/2012-Like antiserum	13/114
B (Victoria lineage)
B/Brisbane/60/2008 antigen	08/352
B/Brisbane/60/2008 like antigen (NYMC BX-35)	10/106
B/Brisbane/60/2008 like antiserum	11/136

Neuraminidase reagents	NIBSC code
N1
Antiserum prepared from A/California/7/2009	10/218
antiserum prepared from A/New Caledonia/20/99	04/230
N2
antiserum prepared from A/Wyoming/3/2003	04/258
B
NA antiserum prepared from B/Jiangsu/10/2003	04/228
NA antiserum prepared from B/Malaysia/2506/2004	05/252
NA antiserum prepared for B/Florida/4/2006	09/316

Southern Hemisphere 2013²

Candidate influenza vaccine viruses	NIBSC code
H1N1
A/California/7/2009 wild type virus	12/174
NYMC X-179A reassortant derived from A/California/7/2009	11/112
NYMC X-181 reassortant derived from A/California/7/2009	11/128
NIBRG-121xp reassortant derived from A/California/7/2009	09/268
NIBRG-122 reassortant derived from A/England/195/2009	09/130
NIB-74xp reassortant derived from A/Christchurch/16/2010(A/California/7/2009 – like)	11/186
H3N2
A/Victoria/361/2011 wild type virus	11/226
IVR-165 reassortant derived from A/Victoria/361/2011	11/220
NIB-79 reassortant derived from A/Victoria/361/2011	11/222
NYMC X-217 reassortant derived from A/Victoria/361/2011	12/100
B
B/Wisconsin/1/2010 wild type virus	11/224
B/Texas/6/2011 wild type virus (B/Wisconsin/1/2010 – like)	11/232
NYMC BX-39 reassortant derived from B/Hubei Wujiagang/158/2009 (B/Wisconsin/1/2010 – like)	12/202
NYMC BX-49 reassortant derived from B/Texas/6/2011 (B/Wisconsin/1/2010 – like)	11/244
NYMC BX-41A reassortant derived from B/Wisconsin/1/2010	11/240

Reagents for influenza vaccine standardisation	NIBSC code
H1N1
A/California/7/2009 (NYMC X-179A) egg derived antigen	N/A
A/California/7/2009 (NYMC X-179A) cell derived antigen	09/174
A/California/7/2009 (NIBRG-121xp) egg derived antigen	09/196
A/California/7/2009 (NYMC X-181)	12/168
A/Christchurch/16/2010 (NIB-74)	10/258
A/Brisbane/10/2010 cell derived antigen	11/134
A/California/7/2009 antiserum	12/108
H3N2
A/Victoria/361/2011 (IVR-165) egg derived antigen	12/114
A/Victoria/361/2011 antiserum	12/116
B
B/Hubei Wujiagang/158/2009 (NYMC BX-39) egg derived antigen	12/106
B/Wisconsin/1/2010 cell derived antigen	12/110
B/Wisconsin/1/2010-like antiserum	12/118

Neuraminidase reagents	NIBSC code
N1
Antiserum prepared from A/California/7/2009	10/218
Antiserum prepared from A/New Caledonia/20/99	04/230
N2
Antiserum prepared from A/Wyoming/3/2003	04/258
B
NA antiserum prepared from B/Jiangsu/10/2003	04/228
NA antiserum prepared from B/Malaysia/2506/2004	05/252
NA antiserum prepared for B/Florida/4/2006	09/316

N/A- Not available

Tbc- to be confirmed

Pricing information

Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to the usual NIBSC handling charge of £70 per vial, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the £70 handling fee.

Calibration of Reagents for Influenza vaccine standardisation

Reference antigens and antiserum reagents for the standardization of vaccines are produced by the following WHO laboratories:

Essential Regulatory Laboratories (ERL)

National Institute for Biological Standards and Control (NIBSC), UK

Center for Biologics Evaluation and Research (CBER), USA

National Institute for Infectious Disease (NIID), Japan

Therapeutic Goods Administration (TGA), Australia

Here is the link to the document providing a generic protocol for the calibration of influenza antigen working reagents by the four WHO Essential Regulatory Laboratories (ERLs):

Generic protocol for the calibration of seasonal/pandemic influenza antigen working reagents by WHO Essential Regulatory Laboratories (PDF, 191kb)

It represents the consensus of the ERLs on the process of assigning a potency value to a newly established influenza antigen reagent for use in potency testing of inactivated influenza vaccines. An influenza antigen working (or reference) reagent is a preparation of inactivated whole virus that has been freeze-dried and calibrated as outlined in this document.